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Results: 979 Pts (63.2 ± 11.6 years, 87.3% male) were studied. Baseline
demographics and angiographic characteristics were similar between groups
with no difference in lesion length, calcification or proximal vessel tortuosity.
There was a significant difference in the rate of bifurcations performed via the
TRA and TFA (29.1% vs. 14.6%, p<0.0001). Parallel wire technique and ret-
rograde recanalisation were used more frequently from the TFA. TRA was
associated with an increased use of anchoring balloons.
Sheath sizes > 6 French were used in 20/979(2%). Larger sheath size was
associated with a higher rate of parallel wire technique (p=0.0004), retrograde
recanalisation (p<0.0001) and tornus use (p=0.027). 
Conclusions: TRA has equivalent success rates to TFA in Pts with similar
lesion characteristics, requires less invasive sheath sizes and allows complex
techniques such as retrograde recanalisation.
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Background: Drug–eluting stents (DES) are known to dramatically reduce
restenosis. However, they are more expansive than bare-metal stents (BMS)
and they require prolonged dual antiplatelet therapy. In France, the French
Society of Cardiology and the “Haute autorité de Santé” have defined recom-
mendations for the use of DES (restricted to patients in high-risk group). 
Aim: The aim of this work was to evaluate our practice (whether these rec-
ommendations were well respected or not in our center). Between November
2007 and January 2008 then November 2008 and January 2009 we evaluated
all Percutaneous Coronary Interventions (PCI).
Results: Two hundred and sixteen (216) patients (mean age 65 ± 13 years,
164 (76 %) were males and, 41 (19%) were diabetics) had a PCI for stable
angina or silent ischemia (47%), unstable angina or acute coronary syndrome
(ACS) ST- (26%), ACS ST+ < 48 hours (24%) or ACS ST+ > 48 hours-1
month (3%). Two hundred and seventy six (276) stents were used, including
35% of DES. The recommendations were well respected in 82% of cases.
However, 27% of BMS were implanted in patients in whom DES were indi-
cated. 
Conclusion: The French’s recommendations for DES are a reference to
help practitioners, but they require to be adapted to each patient, depending on
clinical state and their ability to be treated with prolonged dual antiplatelet
therapy.
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Background: Coronary bifurcation lesions remain a challenge, as lower
success rates and higher reintervention rates persist in this lesion subset. The
ideal strategy to treat such lesions is still debated and data regarding long-term
efficacy and safety of drug-eluting stents in this setting are sparse. 
Objectives: We sought to determine the long-term efficacy and safety of a pro-
visional side branch T-stenting (PTS) strategy for bifurcation lesions in an
unselected population.
Methods: 477 consecutive Pts were treated for bifurcation lesions with
DES (Paclitaxel or Sirolimus-eluting stents) between 2003 and 2005. Data
were entered prospectively into a single-center registry. The PTS strategy was
employed in 92%, with a side-branch stent in 28% and final kissing balloon
inflation in 95%. Five-year follow-up, at a median of 61 months, is available
for 93.5 % of patients.
Results: Angiographic success was achieved in 99%, with 2.5 % in-hos-
pital major adverse cardiac events (MACE, defined as any cardiac death, early
reintervention, Q – or non-Q-wave MI or target vessel revascularisation). The
cumulative rate of MACE was 10.7 % at 1 year, 13.6% at 2 years and 19.7%
at 5 years, including target vessel revascularisation rates of 6.9%, 8.9% and
13%, and cardiac death rates of 3%, 3.7% and 6.7%, respectively. Ischaemia-
driven target lesion revascularisation at 5 years is 7.3%. The cumulative rate
of definite or probable stent thrombosis at long-term is 3.1%, most cases
occurring within the first year (2.5%). The need for reintervention in the long-
term was not predicted by any procedural variable, and not significantly
related to the use of 1 or 2 stents or to the type of stent deployed.
Conclusions: A PTS strategy with first generation drug-eluting stents, was
applicable to over 90% of real-world patients with bifurcation lesions with a
target lesion revascularisation < 10% at 5 years. The rate of very-late stent
thrombosis in this complex lesion subset remains low.
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Purpose: Antiplatelet drugs, including aspirin and clopidogrel have proven
efficacy in atherothrombotic event prevention. However, variability of platelet
response measured in the laboratory has been reported and is a subject of keen
interest. 
Methods: 500 consecutive Pts treated with PCI between Nov 2007 and
Dec 2009 and who had VASP and PFA tests performed were retrospectively
identified from a dedicated database. All Pts were pretreated with a loading
dose of 600mg clopidogrel and had a daily maintenance dose of 75mg, or
150mg if their weight was > 80kg. All Pts were under regular aspirin (160mg/
day). Using VASP >50% and PFA<170 to define aspirin and clopidogrel resis-
tance, we compared Pts who were double non-responders with double
responders.
Results: 246 (49.2%) patients were responders to both aspirin and clopi-
dogrel, while 58 (11.6%) were double non-responders. Multivariate analysis
confirmed statistical significance between hypertensive Pts and double
 TFA (233 patients) TRA (646 patients)P value
Sheath size – 6F 218 (93.6%) 642 (99.4%) <0.0001
Sheath size – 8F 11 (4.7%) 0 (0) <0.0001
Parallel wire 54 (23.2%) 106 (16.4%) 0.029
Side branch technique 7 (3.0%) 41 (6.3%) 0.06
Anchoring balloon 7 (3.0%) 48 (7.4%) 0.017
Retrograde recanalisation 16 (6.9%) 18 (2.8%) 0.009
Procedural time 73.4 +/–41.2min 80.7+/–40.7min 0.03
Contrast use 238.7mls +/–180.2mls 286.2 +/–157.3mls 0.001
Angiographic Success 139 (67.8%) 441 (70.7%) 0.44
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responders (p=0.03) and a higher rate of males (p=0.06) as well as pts with
previous myocardial infarction (p=0.06) in this group. There were no statisti-
cally significant differences in sex, BMI or diabetics.
Additional analysis of response versus weight showed an association with Pts
weighing less than 75kg who were more likely to be double responders
(p=0.02)
 Conclusion: Combined aspirin and clopidogrel non-responsiveness is
found in almost 12% of Pts. The only clinical predictor is weight>75kg.
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Purpose: Chronic total occlusion (CTO) remains one of the last frontiers
of percutaneous coronary intervention (PCI). Recently, a novel “soft”
guidewire (GW) developed for tracking invisible micro-channels (Fielder XT)
became available in France. The purpose of this study was to clarify the risk
factors contributing to PCI success for CTO lesions and evaluate the efficacy
and safety of this GW.
Methods: The study included 166 consecutive Pts with CTO’s (European
CTO Club definition) who underwent primary PCI at our institution between
June 2008 and Feb 2010 by 2 experienced operators. The cohort was divided
into 2 groups: group 1 (n=83), treated before availability of “Fielder XT” GW
in France and group 2 (n=83), treated since availability.
Results: Clinical and angiographic characteristics were similar in both
groups (age 63.9±11.3years, lesion length 23.0±18.1mm, bridging collateral
37.%, tortuosity score 0.16±0.37/1 and calcification score 0.94±1.08/3).
Fielder XT was used in 1 case (1.2%) in group 1 and 67 (80.7%) in group 2.
Micro catheters were used more frequently in group 2 (73.2% vs 56.6%;
p=0.013) and parallel wire technique was less required (16.2% vs 31.3%;
p=0.011). Angiographic success rate was significantly higher in group 2
(84.3% vs 67.5%; p=0.005) with a lower rate of dissection (12.2% vs 24.7%;
p=0.02) and a trend for a lower rate of perforation (4.9% vs 1.2%; p=ns). Pre-
dictors of failure in the total cohort were by multivariate logistic regression
analysis: proximal tortuosity (p=0.048, OR=3.15), absence of bifurcation
(p=0.024, OR=3.39), no visible stump (p<0.0001, OR=6.25), calcification
(p=0.029, OR=1.56) and patient in group 1 (p=0.015, OR=3.37).
Conclusion: Introduction of a dedicated “soft” wire in the CTO treatment
strategy improves the angiographic success rate of PCI with a more simple and
“soft” technique. Multivariate analysis confirmed classical independent predic-
tors of failure but also demonstrated that a new device may influence success
rate.
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Background: Premature discontinuation of antiplatelet therapy is a major
risk factor of stent thrombosis after drug-eluting stent placement leading to an
increased risk of death.
Objectives: We sought to determine by a simple questionnaire the preva-
lence of patients at risk for premature discontinuation of oral antiplatelet
therapy in elective percutaneous coronary intervention (PCI).
Methods: Patients scheduled for elective PCI underwent a routine inter-
view (RI) and a specific questionnaire (SQ) by two independent physicians the
day before the intervention. The SQ was designed to identify bleeding disor-
ders, suspected cancer, planned invasive procedures and self evaluation of
compliance. The final decision of drug eluting stent (DES) implantation was
made by a third independent physician who performed the planned PCI and
who had full access to the patient record. 
Results: At least one contraindication to DES implantation was found in
one third of the study population (82/302, 27%) after the RI. All these patients
were also identified by the SQ. At total of 31 additional patients were identi-
fied by the SQ as non eligible for DES implantation. Active bleeding (n=14)
and scheduled biopsies (n=4) were the two main contraindications to DES
implantation isolated by the SQ. Patients characteristics and angiographic find-
ings identified 59.9% patients (n=181/302) eligible for a DES implantation.
Finally the physician performing the PCI excluded 66.3% of the patients
(n=79/302) who could receive a DES and implanted a bare metal stent (BMS)
instead. This decision was based on the findings of the dedicated questionnaire
on top of the interview in 30 patients (38%) and in 49 patients (62%) for other
reasons.
Conclusions: In elective PCI, a simple questionnaire used before DES
implantation can improve identification of patients at high risk for premature
discontinuation of antiplatelet therapy.
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Background: Homocysteine has pro-thrombotic and pro-inflammatory
properties, it is a risk factor for cardiovascular disease. The prognostic value
of homocysteine in ST elevation myocardial infarction (STEMI) remains
uncertain. Aim: This study evaluates the predictive role of homocysteine level
on short and long term outcome in patients with STEMI. 
Methods and results: In this prospective cohort study, 186 consecutive
patients (mean age 58.4±12.6 years, 162 males, 65 diabetics) with STEMI
were enrolled. Plasma total homocysteine levels were measured within 24h
after admission. Inhospital complications: death, shock, left ventricular insuf-
Variable Double 
responders
Double 
non-responders
P
Male 191 (77.6%) 50 (86.2%) 0.15
Age(yrs) 67.3 +/-10.6 63.8+/-11.5 0.06
Weight (kg) 77.7+/-15.3 79.2+/-14.6 0.48
BMI 25.4+/-7.2 27.2+/-5.4 0.04
Smoking 89 (36.2%) 20 (35.5%) 0.81
Dyslipidaemia 152 (61.8%) 35 (61.4%) 0.96
Diabetes 52 (4.7%) 17 (6.1%) 0.22
Hypertension 159 (64.6%) 29 (50.1%) 0.06
Family history 18 (7.3%) 2 (3.5%) 0.20
Past PCI 88 (35.8%) 19 (33.3%) 0.73
Past CABG 9 (3.7%) 2 (3.5%) 0.96
Past MI 25 (10.1%) 11 (19.2%) 0.11
Weight <75kg 116 (46.8%) 18 (31.0%) 0.02
